Stock Events

Stock Events

Paradigm Biopharmaceuticals Limited 

$0.165176
20
-$0.00-2.35% Thursday 18:17

Statistics

Day High
0.1
Day Low
0.1
52W High
0.3468
52W Low
0.1
Volume
5,000
Avg. Volume
13,414
Mkt Cap
70.78M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

27AugExpected
Q2 2023
Q4 2023
Q2 2024
Q4 2024
Q2 2025
Q4 2025
Next
-0.17
-0.12
-0.07
-0.02
Expected EPS
N/A
Actual EPS
N/A

Financials

-36,122.89%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
33,533.63Revenue
-12.11MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PBIGF. It's not an investment recommendation.
CSL
5
CSL.AU
BHP Group Limited
4
BHP.AU
NEXTDC Limited
4
NXT.AU
Fortescue
3
FMG.AU

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap138.91B
Vertex Pharmaceuticals is a competitor because it also focuses on developing treatments for serious diseases, including those in the biopharmaceutical field similar to Paradigm's focus areas.
Regeneron Pharmaceuticals
REGN
Mkt Cap85.87B
Regeneron Pharmaceuticals competes in the biopharmaceutical sector, particularly in developing innovative medicines for various diseases, overlapping with Paradigm's therapeutic areas.
Gilead Sciences
GILD
Mkt Cap181.18B
Gilead Sciences is a competitor due to its strong presence in the biopharmaceutical industry, focusing on antiviral drugs and other treatments that could compete with Paradigm's product offerings.
AMGEN
AMGN
Mkt Cap237.52B
Amgen is a competitor because of its broad focus on biotechnological medicines, including treatments for inflammatory diseases, which may overlap with Paradigm's research and development efforts.
Biogen
BIIB
Mkt Cap32.03B
Biogen competes with Paradigm in the biopharmaceutical space, especially in the development of therapies for neurological and neurodegenerative diseases.
Abbvie
ABBV
Mkt Cap468.22B
AbbVie is a competitor as it operates in the biopharmaceutical sector with a strong emphasis on research and development in areas that could intersect with Paradigm's interests, such as autoimmune diseases.
Pfizer
PFE
Mkt Cap159.99B
Pfizer is a global pharmaceutical company with a wide range of products that could compete with Paradigm's treatments, especially in the biopharmaceutical and vaccine sectors.
Merck
MRK
Mkt Cap376.37B
Merck & Co. is a competitor because of its extensive research and development in pharmaceuticals that could directly compete with Paradigm's therapeutic areas, including infectious diseases and oncology.
Novartis
NVS
Mkt Cap301.95B
Novartis is a competitor due to its significant investment in research and development in the healthcare sector, including areas that overlap with Paradigm's focus, such as chronic diseases.
Astrazeneca
AZN
Mkt Cap257.42B
AstraZeneca is a competitor because it operates broadly in the biopharmaceutical sector, focusing on various therapeutic areas, including respiratory, cardiovascular, and autoimmune diseases, which may compete with Paradigm's portfolio.

About

Melbourne, Australia-based Paradigm Biopharmaceuticals Limited operates as a drug repurposing company, focusing on the discovery and development of therapeutic products for human application. The company's core offering is an injectable formulation of pentosan polysulfate sodium (PPS), which is being developed to address various medical conditions including osteoarthritis, mucopolysaccharidosis, Ross River virus, Chikungunya virus, and acute respiratory distress syndrome. The company was established in 2014.
Show more...
CEO
Paul John Rennie
Employees
8
Country
Australia
ISIN
AU000000PAR5
WKN
000A12FJ4

Listings

F
DE
P86.F
AU
AU
PAR.AU
STU
DE
P86.STU
MU
DE
P86.MU

0 Comments

Share your thoughts

FAQ

What is Paradigm Biopharmaceuticals Limited stock price today?▼
The current price of PBIGF is $0.17 USD — it has decreased by -2.35% in the past 24 hours. Watch Paradigm Biopharmaceuticals Limited stock price performance more closely on the chart.
What is Paradigm Biopharmaceuticals Limited stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Paradigm Biopharmaceuticals Limited stocks are traded under the ticker PBIGF.
Is Paradigm Biopharmaceuticals Limited stock price growing?▼
PBIGF stock has risen by +65.18% compared to the previous week, the month change is a +10.12% rise, over the last year Paradigm Biopharmaceuticals Limited has showed a -2.84% decrease.
What is Paradigm Biopharmaceuticals Limited market cap?▼
Today Paradigm Biopharmaceuticals Limited has the market capitalization of 70.78M
When is the next Paradigm Biopharmaceuticals Limited earnings date?▼
Paradigm Biopharmaceuticals Limited is going to release the next earnings report on February 24, 2027.
What is Paradigm Biopharmaceuticals Limited revenue for the last year?▼
Paradigm Biopharmaceuticals Limited revenue for the last year amounts to 33,533.63 USD.
What is Paradigm Biopharmaceuticals Limited net income for the last year?▼
PBIGF net income for the last year is -12.11M USD.
How many employees does Paradigm Biopharmaceuticals Limited have?▼
As of August 28, 2026, the company has 8 employees.
In which sector is Paradigm Biopharmaceuticals Limited located?▼
Paradigm Biopharmaceuticals Limited operates in the Health & Wellness sector.
When did Paradigm Biopharmaceuticals Limited complete a stock split?▼
The last stock split for Paradigm Biopharmaceuticals Limited was on February 07, 2025 with a ratio of 5:4.
Where is Paradigm Biopharmaceuticals Limited headquartered?▼
Paradigm Biopharmaceuticals Limited is headquartered in Melbourne, Australia.